Advertisement
Advertisement
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
44.69
USDSponsored
+0.77
+1.76%
Feb 02, 16:00 UTC -5
Closed
After-Market
44.70
+0.01
+0.02%
KNSA Earnings Reports
Positive Surprise Ratio
KNSA beat 18 of 30 last estimates.
60%
Next Report
Date of Next Report
Feb 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
$196.83M
/$0.38
Implied change from Q3 25 (Revenue/ EPS)
+8.84%
/+65.22%
Implied change from Q4 24 (Revenue/ EPS)
+60.63%
/-416.67%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue
On Oct 28, 2025, KNSA reported earnings of 0.23 USD per share (EPS) for Q3 25, missing the estimate of 0.32 USD, resulting in a -30.26% surprise. Revenue reached 180.85 million, compared to an expected 170.71 million, with a 5.95% difference. The market reacted with a -2.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.38 USD, with revenue projected to reach 196.83 million USD, implying an increase of 65.22% EPS, and increase of 8.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.23, missing estimates by -30.26%, and revenue of $180.85M, 5.95% above expectations.
How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q3 2025 earnings?
The stock price moved down -2.88%, changed from $40.60 before the earnings release to $39.43 the day after.
When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Feb 16, 2026.
What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?
Based on 9
analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.38 and revenue of $196.83M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement